Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years old (inclusive).~* Have LDH ≥1.5 x ULN at the screening visit.~* Have PNH diagnosis, confirmed by high sensitivity flow cytometry (granulocyte or monocyte clone \>10%).~* Have Hb less than the lower limit of normal (LLN) at the screening visit.~* Have ferritin greater than/equal to the LLN, or total iron binding capacity (TIBC) less than/equal to ULN at the screening visit, based on central laboratory reference ranges. If a subject is receiving iron supplements at screening, the Investigator must ensure that the subject's dose has been stable for 4 weeks prior to screening, and it must be maintained throughout the study. Subjects not receiving iron at screening must not start iron supplementation during the course of the study.~* Body mass index (BMI) ≤ 35 kg/m2 at the screening visit.~* Have a platelet count of \>50,000/mm3 at the screening visit.~* Have an absolute neutrophil count \>500/mm3 at the screening visit.~Exclusion Criteria:~* Treatment with any complement inhibitor (eg, eculizumab) within 3 months prior to screening.~* Hereditary complement deficiency.~* History of bone marrow transplantation.~* Concomitant use of any of the following medications is prohibited if not on a stable regimen for the time period indicated below prior to screening:~  * Erythropoietin or immunosuppressants for at least 8 weeks~ * Systemic corticosteroids for at least 4 weeks~ * Vitamin K antagonists (eg, warfarin) with a stable international normalized ratio (INR) for at least 4 weeks~ * Iron supplements, vitamin B12, or folic acid for at least 4 weeks~ * Low-molecular-weight heparin for at least 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (SOC) excluding complement inhibitors (Type: NO_INTERVENTION): None
- 1,080mg APL-2 administered subcutaneously twice weekly (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).